Quattro Vascular Pte Ltd Announces CE Mark Approval for Chocolate PTA Balloon Catheter

SINGAPORE, Jan. 17, 2011 /PRNewswire-Asia/ -- Quattro Vascular Pte Ltd (Quattro Vascular), developer of next generation percutaneous technologies for the treatment of peripheral artery disease (PAD) announced today that its flagship product, the Chocolate PTA balloon catheter (Chocolate), has received CE Mark approval.

More than 12 million Europeans suffer from peripheral vascular disease, with less than 25 percent undergoing treatment. Current device-based treatment with atherectomy products, conventional balloons, cutting and other specialty balloons result in unpredictable results, substantial vessel trauma, high dissection rates, severe elastic recoil, and abrupt vessel closure. Even with peripheral stenting, outcomes are disappointing due to high rates of restenosis and stent fracture. Quattro Vascular's mission is to provide an effective interventional tool that will become the primary choice for physicians in the treatment of long, highly diffuse lesions in patients with arterial disease in their lower limbs.

Chocolate, Quattro Vascular's first product, is a highly differentiated angioplasty catheter featuring compartmental, modulated inflation with pillow effects. Its unique advanced design is intended to minimize vascular overstretch and thus reduces injury during angioplasty procedures. In addition, Chocolate's innovative shaft technology consists of a braided shaft and an atraumatic tapered tip designed for greater push performance.

"Chocolate was developed for the treatment of complex lesions and represents the next generation in treatments of PAD," said Dr. Foo Fatt Kah, MD, Managing Director at Luminor Capital, which led Quattro Vascular's last financing round. "We have been very impressed by the pace that the company is progressing in its effort to commercialize this novel technology."

About Quattro Vascular Pte Ltd

Headquartered in Singapore, Quattro Vascular Pte Ltd is a privately held medical device company dedicated to developing next generation product solutions to address the large, unmet clinical needs in the percutaneous treatment of complex vascular disease.